Innocan Pharma focuses on innovative non-opioid solutions for chronic pain management and wellness, with services including pharmaceuticals, human and animal health, and wellness products, self-described.

Innocan Pharma

Dexcel Pharma is a privately owned pharmaceutical company developing, manufacturing, and commercializing innovative and generic products worldwide.

Dexcel Pharma

InnoCan Pharma | 2,261 followers on LinkedIn. (CSE:INNO) (FSE:IP4) (OTCQB:INNPF)
 | InnoCan Pharma is a pharmaceutical company specializing in developing novel therapeutics that harness the unique healing properties of Cannabinoids to improve quality of life. 

OUR ADVANTAGES 
Led by a highly-experienced team with a proven track record of success, InnoCan will leverage Israel’s worldleading medical cannabis research community to develop powerful, Cannabinoid-combined, patent-pending formulas. Our outstanding products will be clinically validated by undertaking Post Marketing Surveillance (PMS) studies and combine smart delivery systems to enhance the potency and efficacy of current products for better results.

Investor at RedC Biotech Ltd.

Smadar Shilo

DeepTech Investor ✮ Digital Transformation & Sustainable Manufacturing (i5.0) ✮ Business & Product Innovation

Zvika Weinshtock

CEO at InnoCan Pharma (CSE:INNO) (FSE:IP4) (OTCQB:INNPF)

Iris Bincovich

Analytical chemist with experience in energetic materials, fuels, oils, pharma and polymers

Nissim Vasilevski

InnoCan Pharma

A Novel Solution: LPT-CBD for Chronic Pain Relief

Innocan is proud to announce the relaunch of its newly updated website

These findings, highlights the long-lasting effects of repeated administration of LPT-CBD to treat chronic pain

We are incredibly proud of Dr. Pergolizzi's well-deserved recognition as one of the most-cited scientists worldwide

We are celebrating our 5th anniversary as a public company. In summary: We have demonstrated stability and achieving milestones in our research that has brought our flagship product "Liposomal CBD" (LPD) from the conceptual phase to the successful FDA Pre IND meeting .

May the New Year bring good news, hope, and peace to us all.

We are very excited about our next steps… https://lnkd.in/ddwAWVSv

Innocan reports: LTP injections https://lnkd.in/dZnEnTqW

I am excited to present Innocan Pharma Wellness next week, at White label expo in London…

Metric
Company Name	Innocan Pharma	Dexcel Pharma
Symbol
MSH ID	COM:INNOCANPHARMA	COM:DEXCEL
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Pharmaceuticals
Country	IL	IL
Stage
Employee Count
Website	innocanpharma.com	dexcel.com
LinkedIn	innocanpharma	dexcel-pharma
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

INNO

COM:INNOCANPHARMA

Innocan Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue